◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksB › BOI

Boiron SA (BOI) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-16

Boiron SA (BOI) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Messimy, France with about 2,364 employees. Its market capitalization is roughly €458 million. In the fiscal year ended 2025-12-31, BOI reported €501M in revenue and €33M in net income.

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.

Interactive charts & full statements →

BOI Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue€501M€488M€493M€534M
Gross Profit€366M€359M€358M€380M
Operating Income (EBIT)€36M€36M€41M€57M
Net Income€33M€11M€36M€45M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BOI Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-312021-12-31
Dividends Paid(€21M)(€23M)(€199M)(€16M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BOI Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets€603M€576M€590M€790M
Total Liabilities€210M€198M€199M€232M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BOI viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

← BOHAll “B” companiesBOIL →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.